0000899243-20-013636.txt : 20200519
0000899243-20-013636.hdr.sgml : 20200519
20200519204632
ACCESSION NUMBER: 0000899243-20-013636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200513
FILED AS OF DATE: 20200519
DATE AS OF CHANGE: 20200519
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAWES KAREN A
CENTRAL INDEX KEY: 0001261506
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 20895472
MAIL ADDRESS:
STREET 1: 579 BELLEVUE AVE
CITY: NEWPORT
STATE: RI
ZIP: 02840
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-13
0
0000730272
REPLIGEN CORP
RGEN
0001261506
DAWES KAREN A
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
1
0
0
0
Common Stock
2020-05-13
4
A
0
722
0.00
A
121556
D
Common Stock
2020-05-18
4
S
0
712
135.76
D
120844
D
Common Stock
2020-05-18
4
S
0
160
136.92
D
120684
D
Common Stock
2020-05-18
4
S
0
269
138.60
D
120415
D
Common Stock
2020-05-18
4
S
0
122
139.32
D
120293
D
Common Stock
2020-05-18
4
S
0
180
140.62
D
120113
D
Common Stock
2020-05-18
4
S
0
77
141.45
D
120036
D
Common Stock
2020-05-18
4
S
0
80
142.45
D
119956
D
Stock Option (Right to Buy)
128.18
2020-05-13
4
A
0
1761
0.00
A
2021-05-13
2030-05-13
Common Stock
1761
1761
D
Ms. Dawes was awarded 722 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020.
$135.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.26 to $136.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$138.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.94 to $138.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$139.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.11 to $139.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$140.62 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.21 to $140.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$141.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.42 to $142.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Award vests in full one year from grant date on May 13, 2021.
/s/ Jeffrey P. Leduc (Attorney in Fact)
2020-05-19